$1B+
RAISED WITH OUR SUPPORT
by our clients across the science and technology sectors. We understand what investors expect because our founder sits on the other side of that table.
01
Most life sciences marketing agencies position around execution: content, campaigns, websites. The larger shops chase big pharma budgets. The smaller boutiques compete on price for deliverables.
HTG occupies a different position entirely: the intersection of commercialization strategy and marketing execution for earlier-stage and mid-stage science companies. Every engagement starts with strategy. The marketing work is always downstream of the commercial objective—closing a funding round, launching into a new indication, building a sales pipeline, or earning credibility with a technical buyer audience.
02
$1B+
RAISED WITH OUR SUPPORT
by our clients across the science and technology sectors. We understand what investors expect because our founder sits on the other side of that table.
125+
SCIENCE COMPANIES SERVED
across diagnostics, medtech, biotech, advanced manufacturing, and climate tech.
~12
CLIENTS PER YEAR, BY DESIGN
Depth depends on knowing each client’s science, market, and competitive position in detail.
$21M
FROM A SINGLE 6-MONTH CAMPAIGN
in attributed revenue for a commercial-stage client entering new market segments.
03
Some of our clients have large, sophisticated internal marketing teams. They work with HTG because we execute specialized programs faster and with deeper domain expertise than their internal teams can: scientific conferences, market intelligence reports, product launch campaigns, KOL programs, technical content, sales enablement. We don’t replace internal teams. We do the high-value, specialized work that sits outside their bandwidth or their specialization, and we do it at a pace that keeps up with how fast this industry moves.
04
We have established relationships with the diagnostics, medtech, and biotech trade press: 360Dx, FierceBiotech, GenomeWeb, MedTech Dive. We know the conferences where your buyers and investors gather. We know the investor community active in this space. We don’t understand your market from the outside. We’re connected to it.
05
Our account strategists are former research program PIs, scientific business development managers, and product launch specialists who have worked with venture capital firms, private foundations, and federal agencies. Our writers hold advanced degrees in the sciences. Our market intelligence team conducts the competitive analysis and buyer research that grounds every strategy. We don’t need you to explain what a lateral flow assay is, what a 510(k) submission means for your launch timeline, or why your Series A pitch has to land differently than your Series B. We already know. That’s time back in your day and depth you can’t hire for at most agencies.
06 ELIZABETH CHABE, CEO
Elizabeth Chabe (MBA) is the founder and CEO of High Touch Group and the author of The Giant’s Ladder: The Science Professional’s Blueprint for Marketing Success. She has spent her career at the intersection of science and commercial strategy, working with diagnostics and medtech founders, advising VC firms, and consulting for national health agencies. Since 2018, she has served as a governor-appointed director of the Maine Venture Fund, where she advises portfolio companies and helps direct strategic investments.
Elizabeth leads strategy on every HTG engagement. On retainer accounts, it means she’s in it with you for the long run. On Sprints, that means a direct session with her. You are not handed off.
Get the BookThe definitive guide for scientists and founders who need to think like marketers.